Relevant Articles About Prostate Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to analyze differences in clinical, molecular, therapeutic, and prognostic factors among spinal chondrosarcoma subtypes. The results showed upregulated p53/MDM2 pathway in MCS and DCS, with radical resection crucial for spinal...
KEY TAKEAWAYS The study aimed to evaluate the expression of USF1 in patients with AML and determine its clinical and prognostic significance. The results showed that high USF1 expression was associated with poor prognosis and reduced survival in patients with AML....
KEY TAKEAWAYS The AXAGIST phase 2 trial aimed to investigate the synergy of axitinib and avelumab in advanced GIST after standard therapy failure. The primary endpoint was to determine PFS. Researchers noted significant efficacy and long-term benefit from the...
The EMBARK phase 3 trial aimed to examine nursing implications of efficacy, safety, and PROs for enzalutamide treatments. The primary endpoint was MFS. …
The PROREPAIR-B, PROSENZA, PROSTAC, and PROSABI observational trial aimed to investigate the impact of HRR gene mutations beyond BRCA2 in patients with mCRPC. …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
Background Novel early-line therapies for advanced (unresectable or metastatic) melanoma are needed to improve the rate of deep and durable responses and increase the proportion of patients with long-term benefit. TILVANCE-301 will evaluate the efficacy and …